Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4786 | tocilizumab Wiki | 0.71 |
| drug2165 | Lopinavir-Ritonavir Wiki | 0.71 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.
Description: This outcome is defined by a composite 1 year post-transplant endpoint of: detection of de novo donor-specific antibodies (dnDSA) (Core Laboratory), acute cellular rejection (ACR) ≥ ISHLT 2R rejection (Core Laboratory), antibody mediated rejection (AMR) ≥ ISHLT AMR 1 (Core Laboratory), hemodynamic compromise rejection in the absence of a biopsy or histological rejection, death, or re-transplantation.
Measure: Proportion of Participants Positive for Event of dnDSA, ACR, AMR, Hemodynamic Compromise, Death or Re-Transplantation - By Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of de novo donor-specific antibodies (dnDSA). dnDSA is a newly developed alloantibody that is against the donor organ.
Measure: Freedom of Detection of de Novo Donor-Specific Antibodies (dnDSA) - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of acute cellular rejection ≥2R (Reference: International Society of Heart and Lung Transplantation [ISHLT] acute cellular rejection-grade 2R or greater severity).
Measure: Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Rejection - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of antibody-mediated rejection defined as ISHLT grade AMR 1 or greater severity.
Measure: Freedom from Antibody Mediated Rejection (AMR) ≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1 - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of hemodynamic compromise (HDC). Hemodynamic compromise is defined by: - Need for inotropic agents due to a Cardiac Index (CI) <2.0 L/min/m^2 or a 25% decrease from baseline, in addition to one of the following: ejection fraction of <40% or a 20% decrease from baseline, and the need for inotropic agents OR fractional shortening of <20% or a 25% decrease from baseline, and the need for inotropic agents.
Measure: Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from development of episode of rejection requiring treatment. Reference: Acute cellular rejection as defined by the 2004 International Society of Heart and Lung Transplantation (ISHLT) grading scale.
Measure: Freedom from Any-Treated Rejection - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: A comparison by treatment group of the incidence of freedom from acute cellular rejection (ACR) ≥ ISHLT 2R rejection. Reference: 2004 International Society of Heart and Lung Transplantation [ISHLT [ grading scale).
Measure: Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Per Patient - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Time from transplant, free of antibody mediated rejection, defined as ISHLT grade AMR 1 or greater will be compared between the treatment groups. Hemodynamic compromise is defined as the need for inotropic agents due to a Cardiac Index (CI) <2.0 L/min/m2 or a 25% decrease from baseline in addition to one of the following: Ejection fraction of <40% or a 20% decrease from baseline, and the need for inotropic agents Fractional shortening of <20% or a 25% decrease from baseline, and the need for inotropic agents
Measure: Freedom from Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: Time from transplant, free of antibody mediated rejection, defined as ISHLT grade AMR 1 or greater will be compared between the treatment groups
Measure: Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection Per Participant - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Incidence of all-cause mortality will be compared between the treatment groups.
Measure: Occurrence of Death - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Incidence of participant(s) being re-listed for transplant will be compared between the treatment groups.
Measure: Occurrence of Re-Listed for Transplantation - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)Description: Incidence of participant(s) re-transplantation will be compared between the treatment groups.
Measure: Occurrence of Re-Transplantation - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: The frequency of events will be compared between the treatment groups.
Measure: Number of Acute Cellular Rejection (≥ International Society of Heart and Lung Transplantation (ISHLT) 2R) Per Patient - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: The frequency of events will be compared between the treatment groups.
Measure: Number of Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group Time: 12 months post-transplantationDescription: The frequency of events will be compared between the treatment groups.
Measure: Number of Rejection Episodes Associated with Hemodynamic Compromise (HDC) Per Participant - by Treatment Group Time: From transplant through 12 months post transplant surgery (12 months)]Description: Per protocol, per clinical research site standard of care.
Measure: Change in Intravascular Ultrasound (IVUS) Measurements From Baseline to 1 Year Post-Transplant- by Treatment Group Time: Baseline (4 to 8 weeks post-transplant), 1 year post-transplantDescription: In accordance with the International Society of Heart and Lung Transplantation (ISHLT) Cardiac Allograft Vasculopathy (CAV) angiographic grading scale.
Measure: Angiographic Evidence of Cardiac Allograft Vasculopathy (CAV) - by Treatment Group Time: 12 months post-transplantationDescription: Incidence of participant loss to follow up will be compared between the treatment groups.
Measure: Participant Loss to follow up - by Treatment Group Time: 12 months post-transplantationDescription: The frequency of serious infections requiring intravenous antimicrobial therapy and need for hospitalization will be compared between treatment groups.
Measure: Occurrence of Serious Infections Requiring Intravenous Antimicrobial Therapy and Need for Hospitalization - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The incidence of tuberculosis will be compared between treatment groups.
Measure: Incidence of Tuberculosis - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The incidence of CMV infection will be compared between treatment groups.
Measure: Incidence of Cytomegalovirus (CMV) Infection - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The incidence of PTLD will be compared between treatment groups.
Measure: Incidence of Post-Transplant Lymphoproliferative Disease (PTLD) - by Treatment Group Time: Through 24 months post transplant surgeryDescription: The number of participants who discontinue study drug, per protocol, will be compared between treatment groups.
Measure: Tolerability (Discontinuation of Study Drug) of Tocilizumab (TCZ) - by Treatment Group Time: Through 24 months post transplant surgeryAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports